IAPB general assembly set for September
March 21st 2012“Eye Health: Everyone's Business” will be the theme of the ninth general assembly of the International Agency for the Prevention of Blindness, which will be held Sept. 17 to 20 in Hyderabad, India. All ophthalmologists, optometrists, and other eye-care service providers and health-care professionals are invited.
Game controllers help identify torticollis
March 21st 2012Remotes for the Nintendo Wii gaming system have been known to do everything from sharpen a player’s tennis skills to help rid the world of zombies. So perhaps it’s not surprising that they can also help identify children who have ocular torticollis.
OT wins Neal Award for Best News Coverage
March 21st 2012Ophthalmology Times was awarded Best News Coverage status at the 58th annual Jesse H. Neal National Business Journalism Awards competition recognizing editorial excellence. The awards were announced and presented March 16 at a ceremony at the Mandarin Oriental in New York City.
Acadia, Allergan extend drug discovery collaboration
March 21st 2012Acadia Pharmaceuticals Inc. and Allergan Inc. will continue to collaborate on drug discovery and development of new therapeutics for glaucoma and other ophthalmic indications through March 2013 under the terms of an extension that adds a year to the research term originally established in March 2003.
Finding clues for unsolved mysteries in glaucoma
March 14th 2012The glaucomas continue to intrigue us with unsolved mysteries. Paul Palmberg, MD, PhD, enumerated several examples during Glaucoma Subspecialty Day at the annual meeting of the American Academy of Ophthalmology. He challenged investigators to find the answers.
Bayer to launch AMD drug in Australia
March 14th 2012Bayer HealthCare plans to launch aflibercept injection (Eylea, also known as VEGF Trap-Eye) for the treatment of patients with neovascular age-related macular degeneration in Australia in the second half of this year after having received approval from the Australian Therapeutic Goods Administration.
DME treatment to be marketed in Europe
March 7th 2012An intravitreal insert with sustained-release fluocinolone acetonide (Iluvien, Alimera Sciences) is approvable for use as a treatment for diabetic macular edema in Europe, according to the outcome of the decentralized procedure for multinational marketing there.
Ocular inflammation drug in phase I study
March 7th 2012EyeGate Pharma has begun enrolling patients with anterior scleritis into a phase I study evaluating the safety and effectiveness of its lead product, dexamethasone phosphate ophthalmic solution 40 mg/ml (EGP-437), which the company believes has multiple indications for inflammatory ocular indications.
Manitoba gains ophthalmology residency program
March 7th 2012The University of Manitoba has initiated an ophthalmology residency program. The 5-year program, which will be sited at Misericordia Health Centre's Buhler Eye Care Centre, marks the first ophthalmology residency program in the province since 1982.
Injections improve acuity in retinal vein occlusion
March 1st 2012The HORIZON Retinal Vein Occlusion Study, an extension study of the BRAVO Study, found that long-term multiple intravitreal injections of ranibizumab were well-tolerated by patients with branch retinal vein occlusion and central retinal vein occlusion.